KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
16.43
+0.03 (0.18%)
Dec 5, 2025, 4:00 PM EST - Market closed
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
$5,281
Profits / Employee
-$752,211
Market Cap
830.48M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KALV News
- 11 days ago - KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 24 days ago - KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Business Wire
- 2 months ago - KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - Business Wire